Deciphex
Deciphex operates a dual-platform digital pathology business combining proprietary AI models with a global network of 250+ subspecialty pathologists to serve NHS trusts via Diagnexia clinical diagnostics and top pharmaceutical companies via Patholytix GLP-compliant preclinical research workflows.
- Company typePrivate
- Founded2017
- HeadquartersGlasnevin, Ireland
- Headcount101–250
- GTM typeB2B
- OfferingSoftware
What Deciphex does
Deciphex is a Dublin-headquartered digital pathology company operating a dual-platform business that combines proprietary AI models with a global network of 250+ subspecialty pathologists to deliver diagnostic and preclinical research services. Its Diagnexia platform serves clinical customers, primarily NHS trusts and healthcare institutions, with per-unit CPT-based primary diagnostics and secondary consults, reducing NHS pathology wait times from approximately two months to two days and integrating with Sectra, Philips, and Leica imaging systems. Its Patholytix platform serves pharmaceutical companies and contract research organizations with GLP-compliant digital pathology workflows for preclinical safety assessments, including the Patholytix Foresight AI decision support tool (developed with Charles River Laboratories) and the first DICOM-native platform for full archival of regulated digital studies.
The company monetizes through recurring per-case clinical billing on Diagnexia and SaaS-style subscription licensing on Patholytix, supported by value-added AI workflow services. Deciphex processes approximately 97,000 cases annually across its network and reports adoption by 27+ NHS trusts and 9 of the top 10 global pharmaceutical companies, with strategic co-development and validation partnerships with Charles River Laboratories and Novartis. Its foundation AI models are trained on one of the world's largest digital pathology image repositories, augmented by the EU BigPicture consortium's three-million-slide repository.
Since founding in 2017 by Donal O'Shea, Deciphex has scaled to approximately 223 employees across Ireland, the UK, US, Canada, and Switzerland, accumulated a dense regulatory footprint (UKAS ISO 15189:2022, CAP, CQC, MHRA GLP, GDPR/HIPAA), and raised over $80M in cumulative equity and debt funding, including a $32.3M Series C led by Molten Ventures in January 2025 and a €15M venture debt facility from Claret Capital Partners in October 2025. Current strategic priorities are US market expansion and UK histopathology market leadership by 2027, supported by ongoing product investment in AI foundation models and the VICT3R initiative for animal-use reduction in preclinical studies.
Deciphex firmographics
Firmographics- Name
- Deciphex
- Legal name
- Deciphex Holdings Limited
- Website
- https://deciphex.com
- Company type
- Private
- Founded year
- 2017
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Deciphex operates a dual-platform digital pathology business combining proprietary AI models with a global network of 250+ subspecialty pathologists to serve NHS trusts via Diagnexia clinical diagnostics and top pharmaceutical companies via Patholytix GLP-compliant preclinical research workflows.
- Ownership category
- akta.pro rank
Deciphex industry classification
Industry- Product category
- Digital Pathology Software
- NAICS
- Medical Laboratories (621511)
- SIC
- Services-Medical Laboratories (8071)
- akta.pro primary industry
- Anatomic Pathology LIS & Digital Pathology Workflow (HLACAMAB)
Keywords
Where Deciphex is headquartered
LocationHeadquarters
- HQ city
- Glasnevin
- HQ country
- Ireland
- HQ region
- Europe
Offices6 records
Markets served
Deciphex business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales
Revenue model
- Diagnexia Clinical Diagnostics Services: Per-case diagnostic pathology services connecting healthcare institutions to global subspecialty pathologists. Pricing based on CPT codes with per-unit activity billing. Services include primary diagnostics, secondary consultations, and turnaround time guarantees.
- Patholytix Pharmaceutical Research Platform: SaaS platform licensing for GLP-compliant digital pathology workflows for pharmaceutical companies and CROs. Enables faster drug compound testing and preclinical safety assessments.
- AI-Enhanced Workflow Services: Value-added services including AI decision support, quality assurance automation, and digital pathology integration that accelerate diagnostic and research workflows.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Per-unit activity billing for pathology services |
| Subscription | Annual | Subscription-based platform access for pharmaceutical research |
Go-to-market motion1 record
Distribution channels5 records
Marketing channels7 records
Deciphex product offering
Product offeringCore offering
Deciphex operates two AI-powered digital pathology platforms. Diagnexia is a clinical diagnostics service connecting hospitals and NHS trusts to a global network of 250+ subspecialty pathologists, delivering rapid histopathology reporting with AI-driven quality controls. Patholytix is a GLP-compliant digital pathology platform for pharmaceutical companies and CROs that enables end-to-end digital preclinical safety studies, including the Patholytix Foresight AI decision support tool co-developed with Charles River Laboratories.
Product overview
Deciphex operates a dual-platform business model serving distinct markets. Diagnexia is the clinical branch providing cloud-based digital pathology diagnostic services that connect hospitals to an international network of subspecialty pathologists for rapid, high-quality diagnostic reports, with fully CQC-registered facilities in Oxford and Exeter. Patholytix is the pharmaceutical research platform providing GLP-compliant digital pathology for preclinical safety assessments, enabling faster drug development through end-to-end digital studies workflows. Both platforms are powered by proprietary AI tools including Foresight for toxicologic pathology decision support, which reduce pathologist review time by over 20% and enable pathologists to work up to 40% faster.
Differentiator
Problem solved
Functional benefit
Brands
- Diagnexia: Clinical digital pathology platform connecting hospitals to international network of subspecialty pathologists for rapid diagnostics and backlog reduction
- Patholytix
- Patholytix Foresight
Products and services
- Diagnexia Clinical digital pathology platform providing world-class diagnostic services to healthcare institutions. Connects hospitals to an international network of subspecialty pathologists for rapid, high-quality diagnostic reports with end-to-end histopathology services from specimen to digital report. Used by 27+ NHS trusts.
- Patholytix GLP-compliant digital pathology platform for pharmaceutical research and preclinical safety assessments. Enables faster, more thorough testing of hundreds of drug compounds with end-to-end digital studies workflows. Used by 9 of top 10 pharmaceutical companies.
- Patholytix Foresight AI-powered decision support tool for toxicologic pathology developed in partnership with Charles River Laboratories. Provides deeper insights into candidate efficacy during Lead Optimization and Dose Range Finding development stages, reducing pathologist review time by over 20%.
- Patholytix 4.0 First DICOM-native platform for full archival and reconstruction of regulated digital studies, ensuring long-term accessibility and interoperability of GLP study data with native DICOMWSI for standardized digital slide storage.
Quantifiable outcome
- 40% faster pathologist productivity while maintaining diagnostic accuracy
- +9 more outcomes
Companies that use Deciphex
Customer profileNamed customers5 records
Segments3 records
Ideal customer profiles3 records
Deciphex technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration4 records
AI capability7 records
Feature7 records
Deciphex partnerships and signals
Strategic signalPartnerships
Six partnerships are on record, tiered strategic, flagship and major.
- ArterastrategicCollaboration to enable UK patients access to Artera's groundbreaking prostate cancer assay that combines hidden morphological signatures from digital pathology images with clinical findings for instant prognostic output.
- Charles River LaboratoriesflagshipMajor strategic partnership since March 2020 for co-development of AI tools to accelerate drug safety assessment. Completed first fully digital GLP study in May 2022. Strategic investor and commercial partner; collaborator on Patholytix Foresight AI decision support tool.
- VICT3R Initiative Partners (33 organizations)majorPublic-private partnership led by Pompeu Fabra University and Bayer AG. €28M IHI JU-funded initiative developing Virtual Control Groups to replace animals in concurrent control groups, reducing animal use by up to 25%. Deciphex contributes AI expertise for this 42-month project.
- NovartisflagshipSeries B investor and strategic collaborator on next-generation foundational AI models for multispecies lesion detection. Provides access to extensive non-clinical datasets from multi-species safety studies for AI model training.
- Janssen PharmaceuticalsmajorPartner in €2M EU Fast Track to Innovation award for AI-driven workflows for preclinical pathology. Collaboration on accelerating development of AI-based workflows for preclinical pathology.
- BigPicture ConsortiummajorEU IMI-funded pan-European initiative building world's largest digital pathology image repository (3 million slides) for AI model validation. Deciphex contributes to and draws from this repository for clinical and non-clinical AI development.
Scale indicators16 records
Recent moves9 records
Expansion highlights6 records
Deciphex competitors and assessment
Company assessmentDirect peers
- Paige.AI: AI-native digital pathology company developing foundation models and diagnostic AI for clinical pathology. Directly comparable in technology stack (AI on whole-slide images), target customer (health systems and pathologists), and category leadership positioning.
- PathAI: AI-powered pathology platform serving both clinical diagnostics and biopharma research, including preclinical safety assessment. Closest direct competitor to Deciphex's dual Diagnexia/Patholytix model with comparable pharma partnerships.
- Ibex Medical Analytics: AI-driven cancer diagnostics platform for clinical pathology, deployed in health systems across the US, Europe, and Israel. Comparable clinical-side competitor with similar AI-on-whole-slide-image approach to Diagnexia.
- Proscia: Digital pathology software company providing AI-enabled workflow and image management solutions to life sciences organizations and clinical labs. Comparable in platform/enterprise software positioning and customer overlap in pharma R&D.
Emerging players
- Owkin: AI biotech company with significant pathology AI initiatives (including MOSAIQ for digital pathology) and biopharma partnerships. Partial overlap in foundation model strategy and pharma data collaborations.
- Aiosyn: AI pathology company developing AI algorithms for clinical and research pathology applications. Emerging peer with overlapping AI-on-pathology focus, particularly in Europe.
- Lunit: Medical AI company with pathology and radiology AI products serving clinical diagnostics and pharma research. Comparable in AI-driven cancer detection and pharma partnership strategy.
Broad incumbents
- Roche Digital Pathology (Ventana): Incumbent digital pathology vendor (via Ventana/Roche) with integrated slide scanners, image management, and companion AI algorithms. Represents the primary enterprise-suite competitive threat to Deciphex's clinical workflow.
- Philips Digital Pathology: Incumbent vendor of enterprise digital pathology solutions, already an integration partner for Deciphex. Comparable in NHS deployments and AI strategy, but operating at much broader scale across imaging and pathology.
Regional players
- Unilabs: Major European diagnostics provider offering pathology and laboratory services across multiple countries. Comparable in clinical pathology services at scale and as a potential EU incumbent competitor to Diagnexia.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat6 records
Key risks6 records
Key highlights7 records
Customer concentration
Deciphex social profiles
Digital presenceDeciphex compliance and trust
Trust signalCompliance8 records
Deciphex financial estimates
Financial estimateRevenue estimate
Valuation estimate
Deciphex leadership team
Management profileNumber of profiles
Profiles12 records
Deciphex subsidiaries and ownership
Company hierarchySubsidiaries4 records
Deciphex funding detail
Funding detailFunding overview
Funding rounds8 records
Investors14 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Deciphex M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Deciphex
What does Deciphex do?
Deciphex operates two AI-powered digital pathology platforms. Diagnexia is a clinical diagnostics service connecting hospitals and NHS trusts to a global network of 250+ subspecialty pathologists, delivering rapid histopathology reporting with AI-driven quality controls. Patholytix is a GLP-compliant digital pathology platform for pharmaceutical companies and CROs that enables end-to-end digital preclinical safety studies, including the Patholytix Foresight AI decision support tool co-developed with Charles River Laboratories.
Is Deciphex a public or private company?
Deciphex is a private company. It is classified as venture growth investor backed and is currently operating.
When was Deciphex founded?
Deciphex was founded in 2017. It employs 101 to 250 people.
Where is Deciphex based?
Deciphex is headquartered in Glasnevin, Ireland, in the Europe region.
How does Deciphex make money?
Three revenue lines are on record. Diagnexia Clinical Diagnostics Services are the primary driver. The others are patholytix Pharmaceutical Research Platform and AI-Enhanced Workflow Services.
Who are Deciphex's main competitors?
Direct peers on record are Paige.AI, PathAI, Ibex Medical Analytics and Proscia. Emerging players are Owkin, Aiosyn and Lunit. Broad incumbents are Roche Digital Pathology (Ventana) and Philips Digital Pathology. Unilabs is listed as a regional player.
Does Deciphex have an API?
No public API is recorded for Deciphex.
What industry is Deciphex in?
Deciphex's product category is Digital Pathology Software. Its primary akta.pro industry code is HLACAMAB, Anatomic Pathology LIS & Digital Pathology Workflow. Its NAICS code is 621511 and its SIC code is 8071.